As one of the crucial components for ADC, antibody drug conjugate linker provides a specific bridge for the stable and efficient delivery of the cytotoxic drug to the target cells during the preparation and storage stages of the ADCs. An ideal linker is supposed to provide competent stability in the process of systemic circulation but take into the efficient and rapid release of the cytotoxic drug in an active form inside the tumor cells. Therefore, it is extremely important to choose the right antibody-drug linkage in the optimization of the therapeutic efficacy and tolerability of ADCs.
Drug Discovery